Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole for Bipolar Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient men and women ages 18-65~* Bipolar I or II disorders, currently depressed mood state based on a SCID for DSM-5; Mixed features in DSM-5 are allowed, but those with a Young Mania Rating Scale score ≥ 15 will be excluded~* Baseline MADRS score ≥ 20~Exclusion Criteria:~* Mood disorders other than bipolar I or II disorders (e.g., bipolar NOS, or cyclothymic disorders, schizophrenia, schizoaffective disorder, or unipolar depression based on the SCID), other disorders, e.g. anxiety disorders, will be allowed~* Current (last 14 days) treatment with an antipsychotic or antidepressant~* History of neuroleptic malignant syndrome or tardive dyskinesia~* Prior history of brexpiprazole use~* Vulnerable populations (e.g., pregnant, nursing, cognitively impaired, incarcerated)~* High risk for suicide defined as \> 1 attempt in past 12 months that required medical attention, any attempt in the past 3 months or current suicidal ideation with plan and intent such that outpatient care is precluded~* Severe or life-threatening medical condition, or laboratory or physical examination findings consistent with serious medical illness (e.g., dangerously abnormal electrolytes)~* Moderate or severe hepatic or renal impairment based on medical history and laboratory analyses~* Taking moderate or strong induces or inhibitors of CYP2D6 or CYP3A4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: EXPERIMENTAL): Brexipiprazole will be taken orally beginning at 0.5 mg/day with an increase to 1 mg/day at week 1 and 2 mg/day at week 2. If reduction in mood symptoms does not occur, the dose will increase to 3 mg/day and 4 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).